Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Purity & Documentation Data Sheet (263 KB) SDS (254 KB) English - EN (254 KB) Franais - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Espaol - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB) Handling Instructions (2659 KB) References [1]
Write this number down
20: Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P
Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects
However, despite the anti-diabetic and anti-obesity functions, of these dual and triple agonists, the long-term safety, cardiovascular, and renal benefits of these multi-target therapies need further validation
Biochemical and preclinical investigations suggest that AOD 9604 affects pathways involved in cellular energy regulation, including cyclic AMP signaling and downstream kinase activation
